How will the New Administration Impact the US Pharma Market?

In January 2021, the U.S. Department of Health and Human Services and the Food and Drug Administration started operating under the new Biden Administration. 

As always, Pharma played an integral part of the 2020 campaign, this session will deep-dive into the changes we can expect for the US market.  

 
Discussion points: 

• Pricing and reimbursement strategies 
• What will the impact be on patients and payers? 
• The realities of reshoring manufacturing, can we expect to see reduced reliance on the East for essential medicines? 
• The R&D and innovation landscape 

This session was originally broadcast as part of CPhI Discover in May 2021